These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 9010862)

  • 21. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient guide to peripheral neuropathy.
    Almadrones LA; Arcot R
    Oncol Nurs Forum; 1999 Sep; 26(8):1359-60. PubMed ID: 10497775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma.
    Dunphy FR; Boyd JH; Kim HJ; Dunphy CH; Harrison BR; Dunleavy TL; Rodriguez JJ; McDonough EM; Minster JR; Hilton JG
    Cancer; 1997 May; 79(10):2016-23. PubMed ID: 9149030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nail toxicity induced by cancer chemotherapy.
    Gilbar P; Hain A; Peereboom VM
    J Oncol Pharm Pract; 2009 Sep; 15(3):143-55. PubMed ID: 19171552
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral glutamine for the prevention of chemotherapy-induced peripheral neuropathy.
    Amara S
    Ann Pharmacother; 2008 Oct; 42(10):1481-5. PubMed ID: 18698011
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Approaches to prevention of the middle to late phase adverse drug reactions in chemotherapy].
    Maeda Y; Sasaki T
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1292-9. PubMed ID: 12146014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical challenges: chemotherapy-induced peripheral neuropathy.
    Paice JA
    Semin Oncol Nurs; 2009 May; 25(2 Suppl 1):S8-19. PubMed ID: 19447319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous reactions to chemotherapy: commonly seen, less described, little understood.
    Sanborn RE; Sauer DA
    Dermatol Clin; 2008 Jan; 26(1):103-19, ix. PubMed ID: 18023774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic therapies for squamous cell carcinoma of the head and neck.
    Kurtin SE
    Semin Oncol Nurs; 2009 Aug; 25(3):183-92. PubMed ID: 19635397
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analyzing current practice patterns: lessons from Amgen's Project ChemoInsight.
    Hayes NA
    Oncol Nurs Forum; 2001 Mar; 28(2 Suppl):11-6. PubMed ID: 11291207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
    Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
    Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of neuromuscular alterations in elders with cancer.
    Visovsky C
    Semin Oncol Nurs; 2006 Feb; 22(1):36-42. PubMed ID: 16458181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing vincristine sulfate medication errors.
    Schulmeister L
    Oncol Nurs Forum; 2004 Sep; 31(5):E90-8. PubMed ID: 15378106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose superselective intra-arterial cisplatin and concomitant radiation (RADPLAT) for advanced head and neck cancer.
    Balm AJ; Rasch CR; Schornagel JH; Hilgers FJ; Keus RB; Schultze-Kool L; Ackerstaff AH; Busschers W; Tan IB
    Head Neck; 2004 Jun; 26(6):485-93. PubMed ID: 15162349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy dose and dose intensity: analyzing data to guide therapeutic decisions.
    Gillespie TW
    Oncol Nurs Forum; 2001 Mar; 28(2 Suppl):5-10. PubMed ID: 11291209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prevention of side reactions--present status and problems--special references].
    Furue H
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1325-30. PubMed ID: 12146019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histopathologic reactions to chemotherapeutic agents.
    Fitzpatrick JE; Hood AF
    Adv Dermatol; 1988; 3():161-83. PubMed ID: 2978953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results.
    Boone SL; Rademaker A; Liu D; Pfeiffer C; Mauro DJ; Lacouture ME
    Oncology; 2007; 72(3-4):152-9. PubMed ID: 18160805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.